Related Experiment Video
Updated: Aug 15, 2025
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Identification and Validation a Necroptosis-Related Prognostic Signature in Cervical Cancer
Zerui Yang1,2, Junren Li3, Yubo Tang4
1Institute of Biological and Medical Engineering, Guangdong Academy of Sciences & National Engineering Research Center for Healthcare Devices & Guangdong Engineering Technology Research Center for Diagnosis and Rehabilitation of Dementia, Guangzhou, 510500, Guangdong, China.
Necroptosis-related genes (NRGs) are key to cervical cancer progression. A new prognostic model using three NRGs accurately predicts patient survival, offering a novel therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Necroptosis is an emerging therapeutic target for cervical cancer.
- The role of differentially expressed necroptosis-related genes (NRGs) in cervical cancer prognosis is not fully understood.
Purpose of the Study:
- To identify differentially expressed NRGs (DE-NRGs) in cervical cancer.
- To develop and validate a prognostic scoring model based on DE-NRGs for cervical cancer patients.
Main Methods:
- Screening of DE-NRGs in cervical cancer tissues.
- Construction and validation of a prognostic scoring model using regression analysis.
- Assessment of model performance using ROC curves, calibration curves, and C-index.
Main Results:
- 17 DE-NRGs were identified in cervical cancer, with most showing high expression.
- Three NRGs were selected as prognostic signature genes.
- The prognostic scoring model accurately predicted patient survival in both TCGA and GEO validation cohorts.
- The risk score was identified as an independent prognostic factor.
Conclusions:
- A novel necroptosis-related prognostic signature for cervical cancer was identified and validated.
- This signature can effectively predict prognosis and guide therapeutic strategies for cervical cancer patients.
